Edward Hall, MD
Retina Specialist · Rochester, NYNPI 1922029503
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,170 of the $38,262 with a category attached, or 73.6%. Genentech USA, Inc. accounts for 83.6% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $21,658 and has fallen 98.4% since, to $354 in 2025. Among retina specialist clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 79 payments — averaging $484.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$32K
- US Retina LLC$4K
- Regeneron Healthcare Solutions, Inc.$679
- AbbVie$445
- Astellas Pharma US Inc$326
- Carl Zeiss Meditec, Inc.$301
- plus $516 from 6 others
Across 92 payments — averaging $2449.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$165K
- Regeneron$18K
- Novartis$18K
- Astellas Pharma Global Development$18K
- Eyepoint US, Inc.$7K
What the payments were for
- Speaking & faculty fees$28,17074%
- Travel & lodging$2,6177%
- Food & beverage$3,1798%
- Gifts$3011%
- Ownership interest$3,99510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 30 | $32,000 |
| US Retina LLC | 6 | $3,995 |
| Regeneron Healthcare Solutions, Inc. | 8 | $679 |
| AbbVie(2 entities) | 15 | $445 |
| Astellas Pharma US Inc | 7 | $326 |
| Carl Zeiss Meditec, Inc. | 1 | $301 |
| Apellis Pharmaceuticals, Inc. | 4 | $183 |
| Alimera Sciences, Inc. | 3 | $133 |
| Hoffmann-la Roche Limited | 1 | $125 |
| Novartis | 2 | $36 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $21 |
| Spark Therapeutics, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$31,611
- VISUCAM Fundus Cameras$301
- EYLEA$226
- Izervay$151
- Non-Covered Product$125
- EYLEA HD$123
- Syfovre$121
- Iluvien$100
How this compares
$38,262 in reported general payments places this provider in the 90th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 352 | $11,881 |
| Brimonidine Tartrate | 49 | $4,151 |
| Ketorolac Tromethamine | 102 | $3,140 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 135 | $1,888 |
| Bromfenac Sodium | 12 | $1,103 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $1,061 |
| Tobramycin | 138 | $637 |
| Dorzolamide Hcl | 19 | $323 |
| Timolol Maleate | 30 | $287 |
| Latanoprost | 33 | $249 |
| Diclofenac Sodium | 11 | $116 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Rochester
- Matthew WitmerRochester$62K
- Brian ConnollyRochester$7K
- Steven RoseRochester$5K
- Vikas KhetanRochester$3K
- Sana IdreesRochester$2K
- Paul HahnNanuet$238K
- Deepika MalikWoodbury$221K
- Szilard KissNew York$195K
- Ferhina AliValhalla$176K
- Donald D'amicoNew York$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.